News

News

  • 2023-03-20
    Biopharmaceutical company Incyte has recently revealed promising results from a clinical trial focusing on the safety and efficacy of povorcitinib in adult patients with extensive vitiligo. The findings were presented at the American Academy of De...
  • 2023-03-18
    Incyte unveiled intriguing 104-week results from its pivotal Phase 3 TRuE-V clinical trial program, which assessed Opzelura® (ruxolitinib) cream 1.5% in nonsegmental vitiligo patients aged 12 and older. These findings, presented at the 2023 Americ...
  • 2023-03-07
    UPDATED: March 7, 2023  Our exclusive analysis will help you understand a higly competitive environment for vitiligo therapies,  the key biotech and pharma companies involved in vitiligo drug development, clinical trial status, pharmacological ac...
  • 2023-02-25
    Boost your weekend mood with some good news:   The European Medicines Agency expressed a positive opinion on Opzelura earlier this week. The green light opens the fast track for it to become the first ‘official’ vitiligo therapy in the EU. Incyte...
  • 2023-02-24
    Great news for the vitiligo community in the EU! Incyte has just announced in a press-release that ruxolitinib cream (Opzelura™) has received a positive opinion from the European Medicines Agency (EMA) committee for the treatment of vitiligo with...
  • 2023-02-22
    Vitiligo is a complex and puzzling autoimmune disorder that causes the loss of pigment-producing cells called melanocytes, leading to white patches on the skin. While the exact cause of vitiligo remains unknown, researchers believe both genetic an...
  • 2023-02-16
    VYNE Therapeutics Inc. recently announced positive results from the Phase 1a portion of its Phase 1a/b clinical trial evaluating its novel BET inhibitor, VYN201, for vitiligo. This drug candidate is a locally administered, small molecule, pan-bro...
  • 2023-02-14
    Just before the Valentine's Day, our Instagram community expressed their ambitions for this year. Amongst the variety of goals shared, two themes emerged - to 'experience something new' and to 'eliminate white spots'.  Here are highlights from ou...
  • 2023-02-08
    In this newsletter, we discuss the latest research, current treatments, and potential developments in the field. Examine the correlations between the incidence of vitiligo and the chemical variables that influence the condition. Read the latest cl...
  • 2023-02-06
    Clinical trials are experiments that test how well new drugs, treatments or devices work in people. Trials progress through Phases I-IV to test a drug candidate, find the appropriate dosage, and look for side effects. The goal is to determine whet...
  • 2023-01-31
    Are you an Adult or Adolescent (age 12 – 17) with nonsegmental vitiligo? Nonsegmental means vitiligo on both sides of your body. If so, you may qualify to take part in a non-treatment research interview study asking you about your experiences wit...
  • 2023-01-27
    Research and treatments for vitiligo have seen a significant increase in recent years, offering new possibilities.  The treatment options for vitiligo are rapidly expanding, with the first Food and Drug Administration-approved treatment leading t...
  • 2023-01-24
    Sharing a nationwide call for teens 12-18 and adults 55-70 years old of any ethnicity with the most common, generalized form of vitiligo. Shoots in NYC next week (travel provided). Pays $1k/shoot + $2k buyout. To respond, please fill out this f...
  • 2023-01-16
    Actress, singer and producer Mamta Mohandas revealed that she is suffering from vitiligo, - on Instagram with a picture of herself and a poem: "Dear Sun ☀️, I embrace you now like I have never before. So Spotted, I’m losing colour… I rise e...
  • 2023-01-10
    Meet 22-year-old Tanya Manhenga, — one of contestants of a hit dating TV show “Love Island.”  Manhenga is one of the ten Islanders who will be in South Africa for six weeks looking for love in the new villa. Love Island UK, winter season 2023, ki...
  • 2023-01-04
    Pune-based startup Ahammune Biosciences has recently completed the phase 1 clinical trials of its investigational new drug AB1001, being developed as a topical therapy for vitiligo.  Dr T. Balganesh, Chairman of Ahammune’s Board said, “Vitiligo i...
  • 2023-01-03
    While 2022 didn't unfold as any of us had hoped, we are grateful for what we accomplished with your support as we look back. The Vitiligo Research Foundation (VRF) has made a notable mark on the world-wide vitiligo community, from providing educat...
  • 2022-12-12
    New research suggests that exposure to phenols and catechols raising the risk of vitiligo onset by 4 times. The study conducted at the University of Sfax in Tunisia indicated the following risk factors for vitiligo: household chemical use hair...
  • 2022-11-14
    Researchers from Northwestern University are conducting a research survey on the use of natural remedies, supplements and camouflage by vitiligo patients, so that dermatologists can provide them with more competent and relevant care. Investigat...
  • 2022-11-01
    As an autoimmune disorder, vitiligo has been associated with anticipated increased risk of disease severity among patients infected with SARS-CoV-2 since the beginning of the pandemic. Conversely, recent study outcomes prove that COVID-19 hospital...
  • 2022-10-29
    REMINDER: Incyte Ingenuity Awards in Vitiligo deadline is October 31st, 2022.  Apply for awards for up to $35,000 or $100,000 to support your initiative! The Incyte Ingenuity Awards in Vitiligo aim to support the vitiligo community by funding tw...
  • 2022-10-17
    Researchers from University of Southern California, Skin of Color and Pigmentary Disorders Program are doing a survey study.  They aim to evaluate perceptions of skin cancer risk and sun protection practices in people with vitiligo.  This anonymo...
  • 2022-08-05
    After a two-year break due to COVID-19, the Master Class on Vitiligo and Pigmentary Disorders is back on track: 2023: 🇹🇷 Istanbul (Turkey), November 8-10 2024: 🇮🇳 Chandigardh (India), November 6-8 2025: 🇺🇸 Boston (USA), November 5-72026: 🇮🇹 Rome ...
  • 2022-07-19
    The U.S. Food and Drug Administration has finally approved a first-of-its-kind treatment for vitiligo by Incyte.  DRUG  Opzelura (1,5% ruxolitinib cream) is the only one* drug approved in the U.S. to restore skin color in people with the most co...
  • 2022-06-30
    Meet us at CILAD* conference in Madrid tomorrow, July 1st at 12 noon, for the discussion of the recent advances in treatment of pigmentary disorders and vitiligo. Speakers:  Dr. Gabriel Serrano Sanmiguel MD, PhD, Dermatólogo y fundador de Sesd...